To investigate the efficacy and safety of a non-calorie–restricted LCD on glycaemic control, body composition, and cardiovascular risk factors in patients with type 2 diabetes, while maintaining their non-insulin antidiabetic medication and physical activity. This evidence concerns the gene INS and type 2 diabetes mellitus.